A new medicine for lupus-related blood clotting problems
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called KP104 for people who have lupus and a related condition where small blood clots form and can damage organs like the kidneys. The goal is to see if the drug is safe and whether it helps improve blood counts and kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with lupus (SLE) by a doctor.
- Your platelet count is low (under 150,000).
- You have kidney problems, such as abnormal kidney function.
- You have anemia caused by red blood cells breaking down (a sign of TMA).
- You are not pregnant and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, MK-1045, for people with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how it affects your condition.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
This trial tests a new treatment called KITE-363 for people with certain autoimmune diseases (like lupus, scleroderma, or inflammatory myositis) that haven't improved with standard treatments. The goal is to see if KITE-363 can reduce disease activity and improve symptoms.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This trial is testing a new investigational drug called QLS4131 in people with systemic lupus erythematosus (SLE), an autoimmune disease where the immune system attacks healthy tissues. The goal is to see if it is safe and effective in reducing disease activity.
This trial tests a fast-acting CAR-T therapy that targets BCMA and CD70 proteins to treat lupus. It may help people with moderate-to-severe lupus that hasn't improved with standard treatments.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.